Abstract 341P
Background
Lean body mass and low muscle mass are associated with survival, quality of life (QOL), and tolerance to treatment in cancer patients. Most early breast cancer patients were reported in overweight and obese nutrition status. There is still limited data evaluating the relationship between muscle mass and QOL in breast cancer patients, especially in early stages. The aim of this study is to examine the relationship between muscle mass and QOL domain in breast cancer patients before underwent chemotherapy.
Methods
A total of 80 breast cancer patients were enrolled in this study. Women breast cancer patients before they underwent chemotherapy were included in this study. Skeletal muscle mass was measured by bioelectrical impedance analysis, and it was reported as the Skeletal Muscle Index (SMI). QoL was assessed using the EORTC-QLQ-C30. The correlation between SMI and QOL was evaluated using Pearson or Spearmen correlation test based on the normality data.
Results
The mean of age was 47.39+7.07 years old. The median of body mass index (BMI) was 23.15(7.86-47.26) kg/m2. The distribution of BMI for underweight, normo-weight, overweight and obese were 5(6.3%); 33(41.3%); 16(21.1%); and 26(32.6%), respectively. Most patients were in early breast cancer 71 of 80 (88.8%). The median of SMI was 5.72(1.91-12.35). The median of QOL global health status, physical function, role function, emotional function, cognitive function, and social function domain were 66.67(0-100); 93.33(0-133.33); 100(0-133.33); 83.33(33.33-100); 100(16.67-100); and 100(0-100), respectively. The correlation between SMI and QOL global health status, physical function, role function, emotional function, cognitive function, and social function domain were (r 0.194, p 0.085); (r 0.021, p 0.851); (r 0.009, p 0.939); (r 0.061, p 0.588); (r 0.280, p 0.012); and (r 0.078, p 0.490), respectively.
Conclusions
Almost all QOL domains of breast cancer patients before underwent chemotherapy showed good results. The relationship between muscle mass and QOL in breast cancer patients before underwent chemotherapy only showed in the cognitive domain. Further studies need to be done to evaluate the physical activity and protein consumption practice with QoL.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
297P - Factors affecting duration of admission in the palliative medicine ward of a tertiary cancer hospital: A pilot, investigator initiated, review of services
Presenter: Rahul D. Arora
Session: e-Poster Display Session
298P - Abandonment of treatment in teenagers and young adults with cancer: A multi institutional survey
Presenter: B S Ankit
Session: e-Poster Display Session
304P - Identification of nine lncRNAs signature for predicting survival benefit of melanoma patients treated with immune checkpoint inhibitors
Presenter: Jian-Guo Zhou
Session: e-Poster Display Session
305P - Novel co-occurring genomic alterations associated with prediction and prognosis in lung adenocarcinoma
Presenter: Xin Zhao
Session: e-Poster Display Session
306P - Detection of anaplastic lymphoma kinase (ALK) mutations using circulating tumour DNA (ctDNA) in advanced non-squamous non-small cell lung cancer (non-Sq-NSCLC) in Asia
Presenter: Kirsty Lee
Session: e-Poster Display Session
307P - Development of circulating free DNA methylation markers for thyroid nodule diagnostics
Presenter: Shuibing Hong
Session: e-Poster Display Session
308P - The genomic landscape of non-small cell lung cancer (NSCLC) in East Asia using circulating tumour DNA (ctDNA) in clinical practice
Presenter: Byoung Cho
Session: e-Poster Display Session
309P - Improved diagnostic accuracy in MRI breast lesions using a classification system and multilayer perceptron neural network
Presenter: Venkata Pradeep Babu Koyyala
Session: e-Poster Display Session
310P - Genomic biomarker detection in East Asian clinical practice using circulating tumour DNA (ctDNA) from patients with gastrointestinal (GI) tract cancers
Presenter: Sadakatsu Ikeda
Session: e-Poster Display Session
311P - Effect of chemotherapy on fatty liver occurrence in breast and gastrointestinal cancer patients
Presenter: Seyed Alireza Javadinia
Session: e-Poster Display Session